Evidence map›Paper›PMID 35258791›Full record

ReviewCurrent treatment options in oncology2022

Which FLT3 Inhibitor for Treatment of AML?

Jayastu Senapati, Tapan Mahendra Kadia

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jayastu SenapatiDepartment of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd. - Unit 428, Houston, 77030, USA.
Tapan Mahendra KadiaDepartment of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd. - Unit 428, Houston, 77030, USA. tkadia@mdanderson.org.ORCID http://orcid.org/0000-0002-9892-9832

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementTreatment options in acute myeloid leukemia (AML) have improved significantly over the last decade with better understanding of disease biology and availability of a multitude of targeted therapies. The use of FLT3 inhibitors (FLT3i) in FLT3-mutated (FLT3

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, Acutefms-Like Tyrosine Kinase 3HumansMutationProtein Kinase InhibitorsTransplantation, HomologousFLT3 protein, humanfms-Like Tyrosine Kinase 3Protein Kinase InhibitorsAMLFLT3 inhibitorGilteritinibMidostaurinQuizartinibSorafenib

Identifiers

PMID35258791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.